Tony's Diary Package — page 648

COVID-19 Vaccines Cheat Sheet: Access Edition (Hirer) BIOTECH Pfizer / BioNTech mRNA moderna Moderna mRNA aed Gamaleya Viral Vector (AdS/Ad26) VY me ° Sinopharm/Beijing Inst. Inactivated #) ORPORD patrazereca 2 Oxford /AstraZeneca Viral vector (ChimpAd) Gehmnenifoheren J&J Viral Vecotr (Ad26) @ sinovac SinoVac Inactivated About Variants 95% (95% Ck: 89.3 -96.8%) 94.5% (95% CE 90.3-97.6) 91.6% (95% 0185-6 - 95.2) 72.5% (standard dose) (95% Ck 52 ~72%) 66.1% (95% Ck: $5.0 -74.8) (95%. CE 35 62%) 299% >99% 99% 99% 299% 299% No No Yes, but efficacy result does not reflect SA data yet Yes No 2 doses / 3 weeks 2 doses / 4 weeks 2 doses / 3 weeks 2 doses / 3 weeks 2 doses / 4. weeks 1 dose 2 doses / 2 weeks Deep freeze Feezer / refrigerator stable for 30 days Feezer TBC Refrigerator stable for 6 months Refrigeration Refrigeration $15-19 $15-37 $10.00 $2-5 $8-10 1,3 Billion 600M-1 Billion 1 Billion 1 Billion Up to 3 Billion 1 Billion 1 Billion US., EU., other countries. US., UK. EU, other countries Early use in Russia. use in other countries Egypt, other countries UK, EU, other countries Emergency use in U.S., Bahrain Brazil, other countries. China, U.ALE., Bahrain. China All viruses mutate, and the SARS-CoV-2 virus is no exception. This means variations in the viral genome occur when the virus replicates; over time, these mutations may get passed along as the virus is transmitted from person to person. Scientists have identified multiple prominent variants of SARS-CoV-2 that are now circulating around the world. How well COVID-19 vaccines protect against emerging variants is a vital question. Vaccines that have been tested more recently, and in places where new variants are circulating widely, offer some answers. For example, the J&J vaccine was found to be 57 percent effective against moderate to severe disease caused by the variant first identified in South Africa (and 66 percent effective against all variant encountered during Ph.3 testing), while the AstraZeneca-Oxford vaccine did not protect clinical trial volunteers from mild or moderate illness against this same variant. The Pfizer/BioNTech and Moderna vaccines -- the first to show high efficacy and gain FDA Emergency Use Authorization -- were tested earlier in the epidemic, before these variants emerged, and scientists are still learning to what degree variants will impact the effectiveness of these vaccines. Vaccines can protect people in multiple ways. They can reduce the likelihood of contracting a disease, reduce the risk of severe illness, and/or reduce the chance of onward transmission. While COVID-19 vaccines show varying levels of protection against symptomatic illness (overall efficacy in the above chart) -- available data from Ph. 3 trials show they have all done a spectacular job at preventing hospitalization and death, even against emerging variants. * Per dose (not including delivery costs) Last updated March 5, 2021 Continued on page 2 '9,000,000/526,200 PRESS: NPR "All Things Considered" with Mary Louise Kelly (done together with Francis Collins); VICE TV Documentary Taping; Gray TV Special with Greta Van Susteren; Did podcast with Tom Inglesby from Hopkins; March 10, 2021 - Global - 117,300-,000/2,600,000; USA - 29,000,000/526,200 Had a very moving tribute to me upon the receipt of the Yale University School of Management "Legend in Leadership" Award from the Chief Executive Leadership Institute. Moving comments by Albert Bourla (Pfizer), Alex Gorsky (J & J). PRESS: CNN "New Day" with John Berman; Interview with Carolyn Johnson of the Washington Post; Instagram with Eugenio Derbez (Mexican-American entertainer) Historical comparison of the vaccine efforts of Trump versus Biden in NY Times article by Sharon La Franiere: